|
Video: What is a Stock Split?
|
|
Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia. According to our Axsome Therapeutics stock split history records, Axsome Therapeutics has had 0 splits. | |
|
Axsome Therapeutics (AXSM) has 0 splits in our Axsome Therapeutics stock split history database.
Looking at the Axsome Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Axsome Therapeutics shares, starting with a $10,000 purchase of AXSM, presented on a split-history-adjusted basis factoring in the complete Axsome Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/20/2015 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$9.07 |
|
End price/share: |
$65.72 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
624.59% |
|
Average Annual Total Return: |
26.54% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$72,462.64 |
|
Years: |
8.41 |
|
|
|
|
|